Summary
Overview
Work History
Education
Skills
What Colleagues Say
Timeline
Generic

Melissa O’Gorman

Westport,CT

Summary

Clinical pharmacology and pharmacometrics leadership spanning 25+ years across discovery, translational sciences, and global clinical development. Focused on shaping clinical pharmacology strategy, guiding programs from IND-enabling stages through pivotal trials, regulatory filings, and post-marketing commitments. Known for bringing clarity to complex scientific and regulatory challenges, strengthening cross-functional alignment, and elevating decision-making through model-informed development. Experience includes representing programs in FDA and global health authority meetings, leading clinical pharmacology strategy for pivotal submissions, and driving department-level standards and scientific governance. Mentorship, talent development, and building high-performing scientific teams remain central to my leadership approach.

Overview

2027
2027
years of professional experience

Work History

Senior Director, Clinical Pharmacology

SpringWorks Therapeutics (acquired by Merck KGaA
2026 - Current
  • Provide portfolio‑level leadership for clinical pharmacology strategy across preclinical, translational, and clinical stages. Lead clinical pharmacology strategy for pivotal submissions, integrating model‑informed drug development (MIDD) analyses—including exposure‑response, population PK, and PBPK modeling—to support DDI evaluation, labeling, and regulatory decision‑making for Ogsiveo and Gomekli. Contribute to clinical pharmacology sections of the drug label through data interpretation, MIDD integration, and regulatory engagement. Represent programs in FDA and global health authority meetings, preparing and delivering clinical pharmacology presentations and responses. Guide IND‑enabling strategy for early‑stage assets, including FIH dose selection and translational modeling. Design and execute postmarketing commitment studies and associated regulatory documentation. Oversee CRO execution of clinical pharmacology studies and modeling deliverables. Co‑author regulatory documents for FDA and global submissions. Develop junior clinical pharmacologists and contribute to department‑level standards and scientific governance.

Director Clinical Pharmacology

Springworks Therapeutics
2024 - 2026
  • Lead clinical pharmacologist responsible for the development and implementation of program specific clinical pharmacology strategies and plans. Design clinical pharmacology study protocols, interpretation and reporting of study data. Represent clinical pharmacology as member of the clinical sub-team and clinical trial working teams. Manage CROs for DMPK and Clinical Pharmacology studies developing study timelines, objectives and budgets; ensure accuracy of project deliverables. Co-author regulatory documents for submission to global health authorities.

Associate Director, Pharmacometrics

Pfizer
Groton, CT
2021 - 2024
  • Develop and execute pharmacokinetic and pharmacodynamic models, including population PK/PD analysis in, Diabetes, Weight Loss, and Cachexia therapeutic areas. ECG/BP analyses to support QTc waiver preparation. Conduct simulations to support clinical trial design at various phases of drug development. Assessment of Probability of Target Value. Prepare modeling and simulation (M&S) analysis plans and reports. Create M&S datasets and/or provide PK and PD dataset specifications to statistical programmers for creation of M&S datasets. Internal SME for various internal analysis tools. Contributions to external presentations and publications.

Senior Manager

NCA Pharmacometrics/Global Clinical Pharmacology
01.2014 - 01.2021
  • Functional lead for clinical Phase 1 (SAD, MAD, DDI, BE/BA, ADME, Special populations) noncompartmental PK analyses across wide range of study designs. Consulting with clinical project team members contributions to clinical study protocols, statistical analysis plans, and delivery of non-compartmental analyses and clinical study reporting. Global portfolio contributions +300 clinical studies. Pivotal in assessing new clinical study designs and standards i.e., microADME studies. Serve as committee co-chair of Clinical Pharmacology Standards Review Board, Internal Process Manger, Clinical Pharmacology Guidance Board and Clinical tables, listing and figures reduction committees. Delivery of process improvements to reduce clinical development cycle times. Instrumental in piloting new clinical software. Led software requirements, design considerations and evaluations for the delivery of new internal software openNCA for noncompartmental analyses.

Manger

Pfizer, Global Clinical Pharmacology Pharmacometrics
01.2009 - 01.2014
  • Responsibilities included clinical PK/PD aspects of protocol design, data analysis, interpretation, and reporting of studies as well as input into strategy for clinical Pharmacology and PK/PD development plans, communication of PK results at the project team level. Experience with controlled release and formulation development. Perform PK-PD modeling and simulations using WinNonlin, Kinetica and NONMEM. Utilization of S-plus or data set building, analysis, and presentation. Contributions to investigative brochures and common technical documents. Lead standardization of PK study outputs and new analysis processes. Evaluated methods studies for postural response as a useful surrogate marker for potential extrapyramidal symptoms in future neuroscience studies.

Senior Associate, Pharmacokineticist

Clinical Pharmacokinetics & Pharmacodynamics, Cardiovascular Metabolic Diseases
01.2002 - 01.2009
  • Conducted noncompartmental analyses for Phase 1 studies including FIH, multiple dose, BE/BA, and DDI trials. Authored Pfizer global NCA guidance and Digoxin methods guidance aligned with FDA expectations. Designed and implemented eNCA, an internal data capture and analysis solution, and contributed to process improvements and software evaluations.

Associate Scientist

Discovery Pharmacokinetics, Dynamics and Metabolism, Cardiovascular Metabolic Diseases
01.1999 - 01.2002
  • Performed ADME and PK/PD studies to support compound nomination, managing end-to-end experimental execution, analysis, and reporting. Presented findings to project teams and contributed to department safety initiatives, earning recognition for improving laboratory safety culture.

Education

MPH - Health Care Administration

New York Medical College School of Health Sciences And Practice
Valhalla, NY

BS - Pharmaceutics

State University of New York At Buffalo, School of Pharmacy
Buffalo, NY

Skills

  • Collaborative leadership
  • Culture transformation
  • Data-driven decision making
  • Selected for high potential leadership development program 2026
  • Extensive Pharmacokinetic(PK)/Pharmacodynamic(PD) experience
  • R, R-Studio-POSIT™, NONMEM®, Phoenix™, MONOLIX™
  • Submissions/Queries/audits
  • Internal guidance best practices
  • Process improvement, Quality Control implementation and global standardization
  • Internal software system development
  • Multiple recipient of WE Upjohn Pfizer Award

What Colleagues Say

"Melissa stepped into a critical situation around a new drug filing, even though her day job was for a different asset, she helped us understand and mitigate critical path activities, her help in this regard was over and above expectations."

"Melissa provided high-quality work to both the design of two complex post marketing clinical trials and responses to both the FDA and EMA for multiple submissions. You are an incredible asset to the team and the company."

"She has shown commitment and high-level technical competence through her collaborations and analyses on the project."

"Melissa just GETS THINGS DONE, which is not something that we can say for too many colleagues."

"Melissa, without your leadership and candor, we would not have been successful."

"I like working with Melissa, probably what I enjoy the most is the fact that she is very firmly set in her convictions and ideas about how things should be, which makes me re-think about my opinion and, either change my mind. From this type of exercise, I only can see a better outcome, since I rather have a team member challenging me, than a regulator."

"I admire Melissa because she is not afraid of speaking her mind (pretty much always in a proper and respectful way) and I would like to encourage her to keep doing that. This company needs people like Melissa, passionate and knowledgeable!"

Timeline

Senior Manager

NCA Pharmacometrics/Global Clinical Pharmacology
01.2014 - 01.2021

Manger

Pfizer, Global Clinical Pharmacology Pharmacometrics
01.2009 - 01.2014

Senior Associate, Pharmacokineticist

Clinical Pharmacokinetics & Pharmacodynamics, Cardiovascular Metabolic Diseases
01.2002 - 01.2009

Associate Scientist

Discovery Pharmacokinetics, Dynamics and Metabolism, Cardiovascular Metabolic Diseases
01.1999 - 01.2002

Senior Director, Clinical Pharmacology

SpringWorks Therapeutics (acquired by Merck KGaA
2026 - Current

Director Clinical Pharmacology

Springworks Therapeutics
2024 - 2026

Associate Director, Pharmacometrics

Pfizer
2021 - 2024

MPH - Health Care Administration

New York Medical College School of Health Sciences And Practice

BS - Pharmaceutics

State University of New York At Buffalo, School of Pharmacy